2017
Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine
Carbone M, Cristoferi L, Cortesi PA, Rota M, Ciaccio A, Okolicsanyi S, Gemma M, Scalone L, Cesana G, Fabris L, Colledan M, Fagiuoli S, Ideo G, Belli LS, Munari LM, Mantovani L, Strazzabosco M. Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine. Biochimica Et Biophysica Acta (BBA) - Molecular Basis Of Disease 2017, 1864: 1415-1422. PMID: 28844954, DOI: 10.1016/j.bbadis.2017.08.025.Peer-Reviewed Original ResearchConceptsClinical outcome indicatorsAutoimmune liver diseaseLiver diseaseMajor autoimmune liver diseasesTertiary clinical centersPrimary sclerosing cholangitisPrimary biliary cholangitisDifferent clinical outcomesNatural history studiesValue of careAutoimmune hepatitisClinical practice environmentJesus BanalesMarco MarzioniNicholas LaRussoPeter JansenSclerosing cholangitisBiliary cholangitisConsecutive patientsClinical outcomesMedian timeCare pathwayClinical centersClinical strategiesValue-based medicine
2008
Type I Autoimmune Hepatitis Presenting With Acute Liver Failure in the Setting of Wild Mushroom Ingestion
Rogart JN, Iyer A, Robert ME, Levy G, Strazzabosco M. Type I Autoimmune Hepatitis Presenting With Acute Liver Failure in the Setting of Wild Mushroom Ingestion. Journal Of Clinical Gastroenterology 2008, 42: 662-666. PMID: 18496396, PMCID: PMC3762257, DOI: 10.1097/mcg.0b013e3181595b7c.Peer-Reviewed Original ResearchConceptsAcute liver failureAutoimmune hepatitisLiver failureType I Autoimmune HepatitisWild mushroom ingestionIndolent presentationInitial manifestationEnvironmental antigensSeventh decadeMushroom ingestionUnusual caseSusceptible individualsHepatitisYoung womenAge rangeDiseaseType IWomenFailureEtiologyAntigenIngestion